Loading your page…
Marketing-authorisation holder · United States
3 medicines in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| MYOSCINTVial | Imciromab pentetate n/a | United States | Not marketed | 1996 |
| REMICADE100mg · Vial | Infliximab | United States | Marketed | 1998 |
| REOPRO2mg/ml · Injectable | Abciximab | United States | Marketed | 1994 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 3 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.
